Daonil 5Mg Tablets 60S (Pack Size 2 X 30S)
Brand : sanofi-aventis pakistan ltd.
How it works
Both in healthy people and in patients with non-insulin dependent (type 2) diabetes mellitus, glibenclamide lowers blood glucose concentration by stimulating insulin release from the betacells of the pancreas. This effect operates in interaction with glucose (improvement in the responsiveness of beta-cells to the physiological glucose stimulus). Glibenclamide is also reported as having extrapancreatic effects: it reduces hepatic glucose production and enhances insulin binding and insulin sensitivity in peripheral tissues.
DAONIL TAB 5 MG 6X10'S
Requires Prescription (YES/NO)
Non-insulin-dependent (type 2) diabetes mellitus, whenever blood glucose levels cannot be controlled adequately by diet, physical exercise, and weight reduction alone.
Headache, ravenous hunger, nausea, vomiting, lassitude, sleepiness, disordered sleep, restlessness, aggressiveness, impaired concentration, alertness and reactions, depression, confusion, speech disorders, aphasia, visual disorders, tremor, pareses, sensory disturbances, dizziness, helplessness, loss of self-control, delirium, cerebral convulsions, somnolence and loss of consciousness up to and including coma, shallow respiration and bradycardia , sweating, clammy skin, anxiety, tachycardia, hypertension, palpitations, angina pectoris, and cardiac arrhythmias .
When not to Use
It must not be used: In patients with insulin-dependent (type 1) diabetes mellitus (for example diabetics with a history of ketoacidosis) ; In treatment of diabetic ketoacidosis ; In treatment of diabetic precoma or coma ; In patients with serious renal dysfunction ; In patients with serious hepatic dysfunction ; In patients hypersensitive to glibenclamide , In patients hypersensitive to any of the excipients ; In pregnant women ; In breast feeding women ; In patients treated with bosentan .
Adults : Initially 2.5mg daily at breakfast , increasing if necessary by 2.5mg daily at weekly intervals ; max 15mg daily ; max single dose 10mg . Children : Not recommended . OR As directed by your physician .
Storage yes or /no
Store this medicine at room temperature, away from direct light and heat.
Treatment of patients with G6PD-deficiency with sulfonylurea agents can lead to hemolytic anaemia. Since glibenclamide belongs to the class of sulfonylurea agents, caution should be used in patients with G6PD-deficiency and a nonsulfonylurea alternative should be considered.
Epidemiological studies suggest that the administration of glibenclamide is associated with an increased risk of cardiovascular mortality, when compared to treatment with metformin or gliclazide. This risk was especially observed in patients with diagnosed coronary diseases.
Clinical signs of hyperglycaemia are: increased urinary frequency, intense thirst, dryness of the mouth, and dry skin. In exceptional stress situations (e.g. trauma, surgery, febrile infections), blood glucose regulation may deteriorate, and a temporary change to insulin may be necessary to maintain good metabolic control. Persons allergic to other sulfonamide derivatives may develop an allergic reaction to glibenclamide as well.
When starting treatment, the patient must be informed about the effects and risks of Glibenclamide and about its interaction with dietary measures and physical exercise; the importance of adequate cooperation must also be stressed.
Always consult your physician before using any medicine.
syr bd 1cc insulin 6mm syringe 1s
disprin 300mg dispersible tablets 100s (pack size 10 x 10s)
panadol 500mg tablets 200s ( pack size 20x10s)